The role of leukotriene modifying agent treatment in neuropsychiatric events of elderly asthma patients: a nested case control study

Table 4 Sub-group analysis, duration of drug use

	Overall NPEs		Sleep disorder		Mood disorder		Anxiety disorder
	OR	CI	OR	CI	OR	CI	OR	CI
Group 4 (0–30 days)
Crude OR	1.58	1.47–1.69	1.50	1.36–1.66	1.44	1.30–1.60	1.51	1.37–1.67
Adjusted^a OR	1.67	1.56–1.79	1.54	1.37–1.71	1.61	1.44–1.79	1.61	1.46–1.78
Group 5 (31–120 days)
Crude OR	1.63	1.47–1.92	1.53	1.27–1.85	1.67	1.36–2.05	1.76	1.46–2.14
Adjusted^a OR	1.77	1.55–2.03	1.58	1.31–1.90	1.83	1.49–2.26	1.37	1.54–2.27
Group 6 (> 120 days)
Crude OR	1.51	1.31–1.75	1.45	1.17–1.81	1.53	1.23–1.90	1.34	1.09–1.66
Adjusted^a OR	1.60	1.38–1.85	1.45	1.20–1.86	1.63	1.36–2.09	1.44	1.17–1.78

Abbreviations: NPE Neuropsychiatric Event, OR Odd Ratio, CI Confidence Interval
^a Adjusted by baseline characteristics in Table 2. Logistic regression was used in this analysis. All analyses have p value under 0.05

ISSN: 2054-7064